KBY Biotech Indexv0.0.34
Search
← Pipeline|INO-2656

INO-2656

Approved
By Inovio
Source: Trial-derived·Trials: 4
Modality
Cell Therapy
MOA
EGFRi
Target
WEE1
Pathway
Hedgehog
LGSSCDCSU
Development Pipeline
Preclinical
~Aug 2010
→ ~Nov 2011
Phase 1
~Feb 2012
→ ~May 2013
Phase 2
~Aug 2013
→ ~Nov 2014
Phase 3
~Feb 2015
→ ~May 2016
NDA/BLA
~Aug 2016
→ ~Nov 2017
Approved
Feb 2018
→ Oct 2029
ApprovedCurrent
NCT07766894
2,486 pts·CSU
2021-01→2025-08·Completed
NCT03034754
759 pts·SCD
2019-09→2029-10·Terminated
NCT06718435
158 pts·CSU
2018-02→TBD·Terminated
+1 more trial
6,011 total pts2 indications
CompletedCurrentUpcoming
Catalysts (3)
2025-08-118mo agoPh3 Readout· CSU
2025-08-167mo agoPh3 Readout· SCD
2029-10-053.5y awayPh3 Readout· SCD
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
Approved
Termina…
Approved
Termina…
Approved
Complet…
Approved
Recruit…
Catalysts
Ph3 Readout
2025-08-11 · 8mo ago
CSU
Ph3 Readout
2025-08-16 · 7mo ago
SCD
Ph3 Readout
2029-10-05 · 3.5y away
SCD
RecruitingCompletedTerminated|StartCompletionToday
Trials (4)
NCTPhaseIndicationStatusNEP
NCT07766894ApprovedCSUCompleted2486SeizFreq
NCT03034754ApprovedSCDTerminated759PANSS
NCT06718435ApprovedCSUTerminated158DOR
NCT03045856ApprovedSCDRecruiting2608OS
Competitors (10)
DrugCompanyPhaseTargetMOA
NiranesiranJohnson & JohnsonPhase 2KIF18AEGFRi
JNJ-5094Johnson & JohnsonPhase 2/3GIP-REGFRi
GSK-2051GSKPhase 1PSMAEGFRi
TAK-2403TakedaPhase 2WEE1BTKi
SovacapivasertibAmgenPhase 3WEE1ALKi
GIL-8529Gilead SciencesPhase 1/2JAK1EGFRi
FixaglumideGenmabPhase 2/3WEE1KIF18Ai
SovarasimodHalozymePhase 1/2WEE1Anti-Tau
207-2754Samsung BiologicsPhase 1/2KRASG12DEGFRi
MavuratamabBlueprint MedicinesNDA/BLABETEGFRi